These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37424676)

  • 61. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
    Wu B; Li T; Chen H; Shen J
    Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom.
    Williams J; Vickerman P; Smout E; Page EE; Phyu K; Aldersley M; Nebbia G; Douthwaite S; Hunter L; Ruf M; Miners A
    Cost Eff Resour Alloc; 2022 Nov; 20(1):60. PubMed ID: 36376920
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost-effectiveness of treating all hepatitis B-positive individuals in the United States.
    Razavi-Shearer D; Estes C; Gamkrelidze I; Razavi H
    J Viral Hepat; 2023 Sep; 30(9):718-726. PubMed ID: 37260095
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
    Kanwal F; Gralnek IM; Martin P; Dulai GS; Farid M; Spiegel BM
    Ann Intern Med; 2005 May; 142(10):821-31. PubMed ID: 15897532
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan.
    Mafirakureva N; Lim AG; Khalid GG; Aslam K; Campbell L; Zahid H; Van den Bergh R; Falq G; Fortas C; Wailly Y; Auat R; Donchuk D; Loarec A; Coast J; Vickerman P; Walker JG
    J Viral Hepat; 2021 Feb; 28(2):268-278. PubMed ID: 33051950
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cost-Effectiveness of Therapeutic Use of Safety-Engineered Syringes in Healthcare Facilities in India.
    Bahuguna P; Prinja S; Lahariya C; Dhiman RK; Kumar MP; Sharma V; Aggarwal AK; Bhaskar R; De Graeve H; Bekedam H
    Appl Health Econ Health Policy; 2020 Jun; 18(3):393-411. PubMed ID: 31741306
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The direct cost of managing patients with chronic hepatitis B infection in Australia.
    Butler JR; Pianko S; Korda RJ; Nguyen S; Gow PJ; Roberts SK; Strasser SI; Sievert W
    J Clin Gastroenterol; 2004; 38(10 Suppl 3):S187-92. PubMed ID: 15602169
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Cost-effectiveness and affordability of strategy for preventing mother-to-child transmission of hepatitis B in China].
    Lin Y; Zhang SX; Yang PC; Cai YL; Zou YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):852-859. PubMed ID: 28738455
    [No Abstract]   [Full Text] [Related]  

  • 69. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
    Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
    Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China.
    Li M; Zhao L; Zhou J; Sun Y; Wu X; Ou X; You H; Kong Y; Jia J
    Lancet Reg Health West Pac; 2021 Nov; 16():100249. PubMed ID: 34590058
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis.
    Zou Z; Fairley CK; Ong JJ; Hocking J; Canfell K; Ma X; Chow EPF; Xu X; Zhang L; Zhuang G
    Lancet Glob Health; 2020 Oct; 8(10):e1335-e1344. PubMed ID: 32971056
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.
    Buti M; Brosa M; Casado MA; Rueda M; Esteban R
    J Hepatol; 2009 Oct; 51(4):640-6. PubMed ID: 19576651
    [TBL] [Abstract][Full Text] [Related]  

  • 73. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.
    Veenstra DL; Sullivan SD; Lai MY; Lee CM; Tsai CM; Patel KK
    Value Health; 2008; 11(2):131-8. PubMed ID: 18380625
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
    Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
    Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues.
    Rapti I; Hadziyannis S
    World J Hepatol; 2015 May; 7(8):1064-73. PubMed ID: 26052395
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Estimating national, regional and provincial cost-effectiveness of introducing childhood 13-valent pneumococcal conjugate vaccination in China: a modelling analysis.
    Lai X; Garcia C; Wu D; Knoll MD; Zhang H; Xu T; Jing R; Yin Z; Wahl B; Fang H
    Lancet Reg Health West Pac; 2023 Mar; 32():100666. PubMed ID: 36785861
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Recognizing the impact of endemic hepatitis D virus on hepatitis B virus eradication.
    Goyal A; Murray JM
    Theor Popul Biol; 2016 Dec; 112():60-69. PubMed ID: 27594346
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis.
    Tamandjou Tchuem CR; Andersson MI; Wiysonge CS; Mufenda J; Preiser W; Cleary S
    Vaccine; 2021 May; 39(23):3141-3151. PubMed ID: 33962836
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hepatocellular carcinoma surveillance based on the Australian Consensus Guidelines: a health economic modelling study.
    Nguyen ALT; Si L; Lubel JS; Shackel N; Yee KC; Wilson M; Bradshaw J; Hardy K; Palmer AJ; Blizzard CL; de Graaff B
    BMC Health Serv Res; 2023 Apr; 23(1):378. PubMed ID: 37076870
    [TBL] [Abstract][Full Text] [Related]  

  • 80. An Economic Evaluation of the Cost-Effectiveness of Opt-Out Hepatitis B and Hepatitis C Testing in an Emergency Department Setting in the United Kingdom.
    Williams J; Vickerman P; Douthwaite S; Nebbia G; Hunter L; Wong T; Ruf M; Miners A
    Value Health; 2020 Aug; 23(8):1003-1011. PubMed ID: 32828211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.